Evidence map›Paper›PMID 38407647›Full record

ArticleEJNMMI radiopharmacy and chemistry2024

Neopentyl glycol-based radiohalogen-labeled amino acid derivatives for cancer radiotheranostics.

Yuta Kaizuka, Hiroyuki Suzuki, Tadashi Watabe, Kazuhiro Ooe, Atsushi Toyoshima, Kazuhiro Takahashi, Koichi Sawada, Takashi Iimori, Yoshitada Masuda, Takashi Uno and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Theranostic Application of Radiohalogens in Nuclear Medicine.Nuclear medicine and molecular imaging · 2025
    Review
  4. Ortho-functionalization of aScientific reports · 2025
    Article
  5. Review
  6. Review
  7. In vivo stableEJNMMI radiopharmacy and chemistry · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Yuta KaizukaGraduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8675, Japan.
Hiroyuki SuzukiGraduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8675, Japan. h.suzuki@chiba-u.jp.ORCID http://orcid.org/0000-0002-9560-4274
Tadashi WatabeDepartment of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.ORCID http://orcid.org/0000-0001-8658-2395
Kazuhiro OoeInstitute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka, 560-0043, Japan.ORCID http://orcid.org/0000-0002-8560-027X
Atsushi ToyoshimaInstitute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka, 560-0043, Japan.
Kazuhiro TakahashiAdvanced Clinical Research Center, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Koichi SawadaDepartment of Radiology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Takashi IimoriDepartment of Radiology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Yoshitada MasudaDepartment of Radiology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Takashi UnoDepartment of Radiology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Kento KannakaGraduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8675, Japan.
Tomoya UeharaGraduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8675, Japan. tuehara@chiba-u.jp.ORCID http://orcid.org/0000-0002-1140-9800
Chiba University · JPChiba University Hospital · JPThe University of Osaka · JPFukushima Medical University · JP

Funding

Japan Society for the Promotion of Science 19K08222Japan Society for the Promotion of Science 22K07686Japan Society for the Promotion of Science 23KJ0302
6 · The paper itself

Abstract

backgroundL-type amino acid transporter 1 (LAT1) is overexpressed in various cancers; therefore, radiohalogen-labeled amino acid derivatives targeting LAT1 have emerged as promising candidates for cancer radiotheranostics. However,

resultsWe designed and synthesized new radiohalogen-labeled amino acid derivatives ([

conclusions[

Indexed as

Amino acidAstatine-211NeopentylRadiohalogenTheranostics

Identifiers

PMID38407647
PMCPMC10897087
OpenAlexW4392157852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.